IP Library Granted Patent US 12691084
Granted Patent B2
US 12691084 · App. 17/627,914 · Granted Jul 28, 2026

Pharmaceutical composition for preventing or treating bone diseases

Inventors: Tae Hoon Lee (Gwangju, KR); Sun Woo Lee (Gwangju, KR); Eun Jin Cho (Gwangju, KR); Sang Hyun Min (Daegu, KR); Geun Joong Kim (Gwangju, KR); Dong Kyu Choi (Daegu, KR)
Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
A61K31/18A61P19/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691084
App. No.
17/627,914
Granted
Jul 28, 2026
Kind
B2
Abstract

A composition according to an embodiment of the present disclosure includes a N-phenyl-methylsulfonamido-acetamide compound represented by Formula 1, useful as a pharmaceutical compound to inhibit osteoclast differentiation and/or formation. The compound exhibits excellent prophylactic or therapeutic effects on various bone diseases including periodontitis and the like. Examples of the N-phenyl-methylsulfonamido-acetamide compound represented by Formula 1 are wherein the compound represented by Formula 1 above is selected from the group consisting of: 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylthio)phenyl)acetamide; 2-(N-(5-chloro-2-methoxyphenyl)methylsulfonamido)-N-(2-(phenylthio)phenyl)acetamide; N-([1,1′-biphenyl]-2-yl)-2-(N-(3-acetylphenyl)methylsulfonamido)acetamide); 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylamino)phenyl)acetamide; 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-phenoxyphenyl)acetamide; and N2-(3,5-dimethylphenyl)-N2-(methylsulfonyl)-N-[2-(phenylthio)phenyl]alanineamide. A method for treating a bone disease caused by hyperdifferentiation of osteoclasts according to an embodiment of the present disclosure includes administering to a subject in need thereof the composition.

Claims (23)

1 . A composition comprising a compound represented by Formula 1 below, or a pharmaceutically acceptable salt thereof:

wherein R 1 is H or C1 to C3 alkoxy;

R 2 and R 3 are each independently H, C1 to C3 alkyl, C1 to C3 acyl or halo;

R 4 is phenyl, phenoxy or phenylamino; and

R 5 is H or C1 to C3 alkyl, and

with the proviso that, when R 4 is phenoxy and R 1 is H, R 2 and R 3 are each not C1 to C3 alkyl.

2 . The composition according to claim 1 , wherein R 1 is H or methoxy; R 2 and R 3 are each independently H, methyl, acetyl or chloro; and R 5 is H or methyl.

3 . A composition comprising a compound represented by Formula 1 below, or a pharmaceutically acceptable salt thereof:

wherein R 1 is C1 to C3 alkoxy, R 2 is H, C1 to C3 alkyl, C1 to C3 acyl or halo, R 3 is halo, R 4 is phenyl, phenylthio, phenoxy or phenylamino, and R 5 is H;

R 1 , R 3 and R 5 are H, R 4 is phenyl, phenoxy or phenylamino, and R 2 is C1 to C3 acyl; or

R 1 is H, R 4 is phenyl, phenoxy or phenylamino, and R 2 , R 3 and R 5 are methyl.

4 . The composition according to claim 1 , wherein the compound represented by Formula 1 above is selected from the group consisting of N-([1,1′-biphenyl]-2-yl)-2-(N-(3-acetylphenyl)methylsulfonamido)acetamide), 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylamino)phenyl)acetamide, and 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-phenoxyphenyl)acetamide.

5 . A method for treating a bone disease, the method comprising administering to a subject having the bone disease a composition comprising an effective amount of a compound represented by Formula 1 below, or a pharmaceutically acceptable salt thereof:

wherein R 1 is H or C1 to C3 alkoxy;

R 2 and R 3 are each independently H, C1 to C3 alkyl, C1 to C3 acyl or halo;

R 4 is phenyl, phenylthio, phenoxy or phenylamino; and

R 5 is H or C1 to C3 alkyl,

wherein the bone disease is at least one selected from the group consisting of osteoporosis, rheumatoid arthritis, periodontitis, Paget's disease, osteomalacia, osteopenia, bone atrophy, and osteoarthritis.

6 . The method of claim 5 , wherein R 1 is H or methoxy; R 2 and R 3 are each independently H, methyl, acetyl or chloro; and R 5 is H or methyl.

7 . The method of claim 5 , wherein R 1 is C1 to C3 alkoxy, R 3 is halo, and R 5 is H;

R 1 , R 3 and R 5 are H, and R 2 is C1 to C3 acyl; or

R 1 is H, and R 2 , R 3 and R 5 are methyl.

8 . The method of claim 5 , wherein the compound represented by Formula 1 above is selected from the group consisting of: 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylthio)phenyl)acetamide; 2-(N-(5-chloro-2-methoxyphenyl)methylsulfonamido)-N-(2-(phenylthio)phenyl)acetamide; N-([1,1′-biphenyl]-2-yl)-2-(N-(3-acetylphenyl)methylsulfonamido)acetamide); 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylamino)phenyl)acetamide; 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-phenoxyphenyl)acetamide; and N2-(3,5-dimethylphenyl)-N2-(methylsulfonyl)-N-[2-(phenylthio)phenyl]alanineamide.